Technical Analysis for KURA - Kura Oncology, Inc.

Grade Last Price % Change Price Change
grade B 15.75 -2.05% -0.33
KURA closed down 2.05 percent on Monday, May 20, 2019, on approximately normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Flat Down
See historical KURA trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Narrow Range Bar Range Contraction -2.05%
NR7 Range Contraction -2.05%
New Uptrend Bullish -3.96%
Pocket Pivot Bullish Swing Setup -3.96%
Calm After Storm Range Contraction -3.96%
Up 3 Days in a Row Strength -3.96%
Calm After Storm Range Contraction -2.17%
Narrow Range Bar Range Contraction -2.17%
180 Bullish Setup Bullish Swing Setup -1.99%

Older signals for KURA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Kura Oncology, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule drug candidates that target cell signaling pathways, which drive the progression of various cancers. The company's lead drug candidate, tipifarnib, an inhibitor of protein farnesylation is in Phase II clinical trials used for the treatment of solid tumors, including thyroid, head, neck, urothelial carcinomas, and salivary cancers with HRAS mutations, as well as patients with peripheral T-cell lymphoma. Its product pipeline also comprise preclinical programs, such as orally-available small molecule inhibitors of extracellular-signal-regulated kinases 1 and 2, such as KO-947 and other backup compounds for the treatment of patients with activating mutations in or other dysregulation of the mitogen-activated protein kinase signaling pathway consisting of mutations in KRAS, BRAF, and NRAS; and orally available, small molecule inhibitors of the menin-MLL interaction for the treatment of patients with acute leukemias involving translocations or partial tandem duplications of the mixed lineage leukemia (MLL) gene. The company was founded in 2014 and is headquartered in La Jolla, California.
Medicine Cancer Solid Tumors Oncology Cancers Cell Signaling Signal Transduction Oncogenes Benzamides Ras Subfamily Binimetinib Blood Cancers Braf Kras Mek Inhibitor
Is KURA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 22.0
52 Week Low 10.2
Average Volume 164,665
200-Day Moving Average 15.4766
50-Day Moving Average 15.7536
20-Day Moving Average 15.731
10-Day Moving Average 16.242
Average True Range 0.7088
ADX 26.94
+DI 29.5926
-DI 16.1419
Chandelier Exit (Long, 3 ATRs ) 15.6336
Chandelier Exit (Short, 3 ATRs ) 16.5764
Upper Bollinger Band 17.1042
Lower Bollinger Band 14.3578
Percent B (%b) 0.51
BandWidth 17.458521
MACD Line 0.1733
MACD Signal Line 0.1598
MACD Histogram 0.0135
Fundamentals Value
Market Cap 314.81 Million
Num Shares 20 Million
EPS -1.53
Price-to-Earnings (P/E) Ratio -10.29
Price-to-Sales 0.00
Price-to-Book 6.41
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.38
Resistance 3 (R3) 16.45 16.31 16.28
Resistance 2 (R2) 16.31 16.15 16.28 16.24
Resistance 1 (R1) 16.03 16.05 15.96 15.96 16.20
Pivot Point 15.89 15.89 15.86 15.86 15.89
Support 1 (S1) 15.61 15.73 15.54 15.54 15.30
Support 2 (S2) 15.47 15.63 15.44 15.26
Support 3 (S3) 15.19 15.47 15.23
Support 4 (S4) 15.12